Fecal Incontinence Treatment
Customize your policy alerts
Sign up for EmblemHealth Policy MG.MM.ME.63bC5 alerts
Get alerted when Policy MG.MM.ME.63bC5 changes without checking for updates manually.
Monitor payer policy activity
This clinical guideline defines when treatments and procedures for severe fecal incontinence are considered medically necessary or not for EmblemHealth members and describes required documentation for medical review.
Autologous muscle cell therapy (injection of muscle progenitor cells into the external anal sphincter) is listed as investigational / not considered medically necessary, effective 1/1/2026 (code 1001T).
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.